Avidity Biosciences Inc
NASDAQ:RNA
Avidity Biosciences Inc
Revenue
Avidity Biosciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Avidity Biosciences Inc
NASDAQ:RNA
|
Revenue
$9.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$29.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
See Also
What is Avidity Biosciences Inc's Revenue?
Revenue
9.6m
USD
Based on the financial report for Dec 31, 2023, Avidity Biosciences Inc's Revenue amounts to 9.6m USD.
What is Avidity Biosciences Inc's Revenue growth rate?
Revenue CAGR 5Y
91%
Over the last year, the Revenue growth was 4%. The average annual Revenue growth rates for Avidity Biosciences Inc have been 12% over the past three years , 91% over the past five years .